<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochlorideÂ injectionÂ </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Hydralazine Hydrochloride Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="cfc2950b-cbce-4e08-aaf8-9fbba8df0096"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Rx only</p>
<p>Hydralazine Hydrochloride Injection, USP is an antihypertensive available in a 2 mL vial for intravenous and intramuscular administration.Â  Each mL of the sterile, nonpyrogenic colorless solution contains hydralazine hydrochloride USP, 20 mg; methylparaben NF, 0.65 mg; propylparaben NF, 0.35 mg; propylene glycol USP, 103.6 mg, and Water for Injection USP q.s.Â  The pH of the solution is 3.4 to 4.4. pH may be adjusted with hydrochloric acid and/or sodium hydroxide.Â  Hydralazine hydrochloride is 1-hydrazinophthalazine monohydrochloride, and its structural formula is:</p>
<p>Â <br><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f34904dc-c945-4de4-8594-34e4f4ac1983&amp;name=hydralazine-hydrochloride-injection-usp-figure-1-hydral-struc.jpg">Â </p>
<p>Hydralazine hydrochloride USP is a white to off-white, odorless crystalline powder.Â  It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether.Â  It melts at about 275Â°C, with decomposition.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="d1314791-8e53-4126-b379-0eeffd3272d6"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system.Â  Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.Â  Hydralazine, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.</p>
<p>The peripheral vasodilating effect of hydralazine results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>; and an increased heart rate, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.Â  The preferential dilatation of arterioles, as compared to veins, minimizes <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> and promotes the increase in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.Â  Hydralazine usually increases renin activity in plasma presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge.Â  This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption.Â  Hydralazine also maintains or increases renal and cerebral blood flow.</p>
<p>The average maximal decrease in blood pressure usually occurs 10-80 minutes after administration of hydralazine hydrochloride injection.Â  No other pharmacokinetic data on hydralazine hydrochloride injection are available.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a9b3580d-1ba7-4b08-8999-fd21f5c1157f"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> when the drug cannot be given orally or when there is an urgent need to lower blood pressure.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="cd714269-2547-41d7-a384-0403d183df81"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to hydralazine, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, mitral valvular rheumatic heart disease.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="f5513bfe-8d1f-45ff-a794-4df113e8d4f6"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In a few patients, hydralazine may produce a clinical picture simulating <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> including <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>.Â  In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.Â  Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later.Â  Long-term treatment with steroids may be necessary (see <a href="#e6e77576-2be6-4fa1-a0bd-ba7382360c8c">PRECAUTIONS</a><span class="Bold Italics"><span class="Emphasis"><a href="#e6e77576-2be6-4fa1-a0bd-ba7382360c8c">, Laboratory Tests</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fcd6b8fb-477b-430b-813b-44032608c366"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="bcb8ca93-9a8d-43da-82d0-4950ab62cd56"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Myocardial stimulation produced by hydralazine can cause <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attacks</span> and ECG changes of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>.Â  The drug has been implicated in the production of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.Â  It must, therefore, be used with caution in patients with suspected <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
<p>The â€œhyperdynamicâ€? circulation caused by hydralazine may accentuate specific cardiovascular inadequacies.Â  For example, hydralazine may increase pulmonary artery pressure in patients with mitral valvular disease.Â  The drug may reduce the pressor responses to epinephrine.Â  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> may result from hydralazine but is less common than with ganglionic blocking agents.Â  It should be used with caution in patients with cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>.</p>
<p>In hypertensive patients with normal kidneys who are treated with hydralazine, there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate.Â  In some instances where control values were below normal, improved renal function has been noted after administration of hydralazine.Â  However, as with any antihypertensive agent, hydralazine should be used with caution in patients with advanced renal damage.</p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuritis</span>, evidenced by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, has been observed.Â  Publishing evidence suggests an antipyridoxine effect and that pyridoxine should be added to the regimen if symptoms develop.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e6e77576-2be6-4fa1-a0bd-ba7382360c8c"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests<br>
</h2>
<p class="First">Complete blood counts and <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span> titer determinations are indicated before and periodically during prolonged therapy with hydralazine even though the patient is asymptomatic.Â  These studies are also indicated if the patient develops <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, continued <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or other unexplained signs or symptoms.</p>
<p>A positive <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span> titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with hydralazine hydrochloride.</p>
<p><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span>, consisting of reduction in hemoglobin and red cell count, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, have been reported.Â  If such abnormalities develop, therapy should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c7c17f83-55fe-4e77-9b7b-ae9fa1db44a3"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">MAO inhibitors should be used with caution in patients receiving hydralazine.</p>
<p>When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>.Â  Profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> may occur when diazoxide injection and hydralazine hydrochloride injection are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e8cdd758-ce00-4d34-8a6f-db0c14dc79d5"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">In a lifetime study in Swiss albino mice, there was a statistically significant increase in the incidence of lung tumors (<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and adenocarcinomas) of both male and female mice given hydralazine continuously in their drinking water at a dosage of about 250 mg/kg per day (about 80 times the maximum recommended human dose).Â  In a 2-year carcinogenicity study of rats given hydralazine by gavage at dose levels of 15, 30 and 60 mg/kg/day (approximately 5 to 20 times the recommended human daily dosage), microscopic examination of the liver revealed a small, but statistically significant increase in benign neoplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> in male and female rats from the high-dose group and in female rats from the intermediate-dose group.Â  Benign interstitial cell tumors of the testes were also significantly increased in male rats from the high-dose group.Â  The tumors observed are common in aged rats and a significantly increased incidence was not observed until 18 months of treatment.Â  Hydralazine was shown to be mutagenic in bacterial systems (Gene Mutation and DNA Repair) and in one of two rats and one rabbit hepatocyte <span class="Italics"><span class="Emphasis">in vitro</span></span> DNA repair studies.Â  Additional <span class="Italics"><span class="Emphasis">in vivo</span></span> and <span class="Italics"><span class="Emphasis">in vitro</span></span> studies using <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, germinal cells and fibroblasts from mice, bone marrow cells from Chinese hamsters and fibroblasts from human cell lines did not demonstrate any mutagenic potential for hydralazine.</p>
<p>The extent to which these findings indicate a risk to man is uncertain.Â  While long-term clinical observation has not suggested that human cancer is associated with hydralazine use, epidemiologic studies have so far been insufficient to arrive at any conclusions.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d6e471b0-8172-4071-8cdc-7ee880978236"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Teratogenic Effects</span></span></p>
<p>Pregnancy Category C</p>
<p>Animal studies indicate that hydralazine is teratogenic in mice at 20-30 times the maximum daily human dose of 200-300 mg and possibly in rabbits at 10-15 times the maximum daily human dose, but that it is nonteratogenic in rats.Â  Teratogenic effects observed were <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and malformations of facial and cranial bones.</p>
<p>There are no adequate and well-controlled studies in pregnant women.Â  Although clinical experience does not include any positive evidence of adverse effects on the human fetus, hydralazine should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ec5378b9-be61-4fcf-b848-7f4c7f1d3f9f"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">It is not known whether this drug is excreted in human milk.Â  Because many drugs are excreted in human milk, caution should be exercised when hydralazine injection is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b31b83ec-ba2f-4d1f-836b-99253770e978"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established in controlled clinical trials, although there is experience with the use of hydralazine hydrochloride in pediatric patients.Â  The usual recommended parenteral dosage, administered intramuscularly or intravenously, is 1.7-3.5 mg/kg of body weight daily, divided into four to six doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d5d54b2f-efeb-41cd-8181-c0e91f22639b"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions with hydralazine hydrochloride are usually reversible when dosage is reduced.Â  However, in some cases it may be necessary to discontinue the drug.Â  </p>
<p>The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.</p>
<p><span class="Bold"><span class="Emphasis">Common:</span></span>Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<p><span class="Bold"><span class="Emphasis">Less Frequent:</span></span>Â <span class="Italics"><span class="Emphasis">Digestive</span></span>-<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular</span></span> - <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, paradoxical pressor response, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p><span class="Italics"><span class="Emphasis">Respiratory</span></span> - <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Italics"><span class="Emphasis">Neurologic</span></span> - <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, evidenced by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> characterized by <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
<p><span class="Italics"><span class="Emphasis">Genitourinary</span></span> - difficulty in urination.</p>
<p><span class="Italics"><span class="Emphasis">Hematologic</span></span> - <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, consisting of reduction in hemoglobin and red cell count, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>; <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Italics"><span class="Emphasis">Hypersensitive Reactions</span></span> - <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, pruritis, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Italics"><span class="Emphasis">Other</span></span> - <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f249ba9f-dd9f-43a8-a696-81abeb405997"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="fcc7eb67-f6d5-4f8f-8785-dd75720bb18d"></a><a name="section-8.1"></a><p></p>
<h2>Acute Toxicity<br>
</h2>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> have been reported.</p>
<p>Â Â Â Â Â  Highest known dose survived: adults, 10 g orally.</p>
<p>Â Â Â Â Â  Oral LD<span class="Sub">50</span> in rats: 173 and 187 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f4b89b28-7e1e-4400-91a2-83196873dd32"></a><a name="section-8.2"></a><p></p>
<h2>Signs and Symptoms<br>
</h2>
<p class="First">Signs and symptoms of overdosage include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and generalized skin <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
<p>Complications can include <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and subsequent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, and profound <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="dfe89d6d-3296-4ace-abfe-74d3c825374c"></a><a name="section-8.3"></a><p></p>
<h2>Treatment</h2>
<p class="First">There is no specific antidote.</p>
<p>Support of the cardiovascular system is of primary importance.Â  <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span> should be treated with plasma expanders.Â  If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>.Â  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> responds to beta blockers.Â  Digitalization may be necessary, and renal function should be monitored and supported as required.</p>
<p>No experience has been reported with extracorporeal or peritoneal dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b3aed596-6152-4d4a-b66f-a0d80f205692"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein.Â  Hydralazine Hydrochloride Injection should be used only when the drug cannot be given orally.Â  The usual dose is 20-40 mg, repeated as necessary.</p>
<p>Certain patients (especially those with marked renal damage) may require a lower dose.Â Â  Blood pressure should be checked frequently.Â  It may begin to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within a few minutes after injection, with the average maximal decrease occurring in 10-80 minutes.Â  In cases where there has been <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>, lowering the blood pressure may increase <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>.Â  Most patients can be transferred to oral hydralazine hydrochloride within 24-48 hours.</p>
<p>The product should be used immediately after the vial is opened.Â  The product should not be added to infusion solutions.Â  Hydralazine Hydrochloride Injection may discolor upon contact with metal; discolored solutions should be discarded.Â  </p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ee8df9d4-4505-48ad-8fee-5ff4c2b0882a"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">601401Â Â  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-614-01Â  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Hydralazine Hydrochloride Injection, USP, 20 mg/mL, 1 mL fill, in a 2 mL single dose vial, 25 vials per tray.</p></td>
</tr>
</tbody></table>
<p class="First">This container closure is not made with natural rubber latex.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e5cfa6c2-b525-419a-85c5-1719955c401f"></a><a name="section-11"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f34904dc-c945-4de4-8594-34e4f4ac1983&amp;name=hydralazine-hydrochloride-injection-usp-figure-2-fklogo.jpg"></div>
<p class="First">45854E</p>
<p>Revised: September 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="f6dffdf4-4bf8-458b-9644-f5dc0850f605"></a><a name="section-12"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL -Â  PRINCIPAL DISPLAY - Hydralazine 1 mL Single Dose Vial Label</span></span><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-614-01</p>
<p>601401</p>
<p><span class="Bold"><span class="Emphasis">Hydralazine Hydrochloride Injection, USP</span></span></p>
<p>2<span class="Bold"><span class="Emphasis">0 mg/mL</span></span></p>
<p>For IM or IV Use</p>
<p><span class="Bold"><span class="Emphasis">1 mL</span></span></p>
<p>Rx only</p>
<p>Single Dose Vial</p>
<p>Warning: Discard Unused Portion.</p>
<p><img alt="601401-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f34904dc-c945-4de4-8594-34e4f4ac1983&amp;name=hydralazine-hydrochloride-injection-usp-figure-3-601401-vial.jpg"></p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL -Â  PRINCIPAL DISPLAY - Hydralazine 1 mL Single Dose Vial Tray Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-614-01</p>
<p>601401</p>
<p><span class="Bold"><span class="Emphasis">Hydralazine Hydrochloride Injection, USP</span></span></p>
<p>2<span class="Bold"><span class="Emphasis">0 mg/mL</span></span></p>
<p>For Intramuscular or Intravenous Use</p>
<p><span class="Bold"><span class="Emphasis">1 mL </span></span>Single Dose Vial<span class="Bold"><span class="Emphasis"><br></span></span></p>
<p>Rx only</p>
<p><img alt="601401-tray" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f34904dc-c945-4de4-8594-34e4f4ac1983&amp;name=hydralazine-hydrochloride-injection-usp-figure-4-601401-tray.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDRALAZINE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">hydralazine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-614</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDRALAZINE HYDROCHLORIDE</strong> (HYDRALAZINE) </td>
<td class="formItem">HYDRALAZINE HYDROCHLORIDE</td>
<td class="formItem">20Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">103.6Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">0.65Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">0.35Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-614-01</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040388</td>
<td class="formItem">09/05/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE(63323-614)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>73a3cb12-0ac4-4e79-9d5d-6697bfd71db3</div>
<div>Set id: f34904dc-c945-4de4-8594-34e4f4ac1983</div>
<div>Version: 2</div>
<div>Effective Time: 20131218</div>
</div>
</div>Â <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
